The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)
Open accessAbstract
PURPOSE: As yet, no checkpoint inhibitor has been approved to treat nasopharyngeal carcinoma (NPC). This study was aimed to evaluate the antitumor activity, safety, and biomarkers of toripalimab, a new programmed death-1 (PD-1) inhibitor for recurrent or metastatic NPC (RM-NPC) refractory to standard chemotherapy. PATIENTS AND METHODS: In this single-arm, multicenter phase II study, patients with RM-NPC received 3 mg/kg toripalimab once every 2 weeks via intravenous infusion until confirmed disease progression or unacceptable toxicity. The primary end point was objective response rate (ORR). The secondary end points included safety, duration of response (DOR), progression-free survival (PFS), and overall survival (OS). RESULTS: Among all 190 patients, the ORR was 20.5% with median DOR 12.8 months, median PFS 1.9 months, and median OS 17.4 months. Among 92 patients who failed at least two lines of systemic chemotherapy, the ORR was 23.9%. The ORRs were 27.1% and 19.4% in PD-L1+ and PD-L1− patients, respectively ( P = .31). Patients with ≥ 50% decrease of plasma Epstein-Barr virus (EBV) DNA copy number on day 28 had significantly better ORR than those with < 50% decrease, 48.3% versus 5.7% ( P = .0001). Tumor mutational burden had a median value of 0.95 muts/mega-base in the cohort and had no predictive value for response. Whole-exome sequencing results from 174 patients revealed that the patients with genomic amplification in 11q13 region or ETV6 genomic alterations had poor responses to toripalimab. CONCLUSION: The POLARIS-02 study demonstrated a manageable safety profile and durable clinical response of toripalimab in patients with chemorefractory metastatic NPC. An early decrease in plasma EBV DNA copy number correlated with favorable response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
Chen, Y.-P., Chan, A. T. C., Le, Q.-T., Blanchard, P., Sun, Y., & Ma, J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30956-0 · Cited by 3,077
Self-citationCurrent cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
Feng, R., Zong, Y., Cao, S., & Xu, R. (2019) · Cancer Communications · doi:10.1186/s40880-019-0368-6 · Cited by 1,625
Self-citationThe Enigmatic Epidemiology of Nasopharyngeal Carcinoma
Chang, E. T., & Adami, H.-O. (2006) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0353 · Cited by 1,297
Chow, L. Q. M., Haddad, R., Gupta, S., Mahipal, A., Mehra, R., Tahara, M., Berger, R., Eder, J. P., Burtness, B., Lee, S.-H., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.68.1478 · Cited by 857
Zhang, L., Huang, Y., Hong, S., Yang, Y., Yu, G., Jia, J., Peng, P., Wu, X., Lin, Q., Xi, X., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31388-5 · Cited by 522
Fang, W., Yang, Y., Ma, Y., Hong, S., Lin, L., He, X., Xiong, J., Li, P., Zhao, H., Huang, Y., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30495-9 · Cited by 489
Hsu, C., Lee, S.-H., Ejadi, S., Even, C., Cohen, R. B., Le Tourneau, C., Mehnert, J. M., Algazi, A., van Brummelen, E. M. J., Saraf, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.3675 · Cited by 464
Cited by
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Naimi, A., Mohammed, R. N., Raji, A., Chupradit, S., Yumashev, A. V., Suksatan, W., Shalaby, M. N., Thangavelu, L., Kamrava, S., Shomali, N., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00854-y · Cited by 507
Yang, Y., Qu, S., Li, J., Hu, C., Xu, M., Li, W., Zhou, T., Shen, L., Wu, H., Lang, J., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00302-8 · Cited by 462
Self-citationMai, H.-Q., Chen, Q.-Y., Chen, D., Hu, C., Yang, K., Wen, J., Li, J., Shi, Y.-R., Jin, F., Xu, R., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01444-0 · Cited by 396
Self-citationKaplon, H., Chenoweth, A., Crescioli, S., & Reichert, J. M. (2022) · mAbs · doi:10.1080/19420862.2021.2014296 · Cited by 331
Mai, H.-Q., Chen, Q.-Y., Chen, D., Hu, C., Yang, K., Wen, J., Li, J., Shi, Y., Jin, F., Xu, R., et al. (2023) · JAMA · doi:10.1001/jama.2023.20181 · Cited by 279
Self-citation
Metadata
- Authors
- Wang, F.-H., Wei, X.-L., Feng, J., Li, Q., Xu, N., Hu, X.-C., Liao, W., Jiang, Y., Lin, X.-Y., Zhang, Q.-Y., Yuan, X.-L., Huang, H.-X., Chen, Y., Dai, G.-H., Shi, J.-H., Shen, L., Yang, S.-J., Shu, Y.-Q., Liu, Y.-P., Wang, W., Wu, H., Feng, H., Yao, S., & Xu, R.-H.
- Venue
- Journal of Clinical Oncology
- Published
- 2021-03-01
- Volume
- 39
- Issue
- 7
- Pages
- 704-712
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W3124559501
- Cited by
- 348
- References
- 32
- FWCI
- 44.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). https://app.cochat.ai/papers/10.1200/jco.20.02712
- The paper
- Wang, F.-H., Wei, X.-L., Feng, J., Li, Q., Xu, N., Hu, X.-C., Liao, W., Jiang, Y., Lin, X.-Y., Zhang, Q.-Y., Yuan, X.-L., Huang, H.-X., Chen, Y., Dai, G.-H., Shi, J.-H., Shen, L., Yang, S.-J., Shu, Y.-Q., Liu, Y.-P., . . . Xu, R.-H. (2021). Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02). Journal of Clinical Oncology. https://doi.org/10.1200/jco.20.02712
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
